Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2018-12-17 Director's Dealing
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Director Dealings
Director's Dealing Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from MaxCyte, Inc. regarding 'Director Dealings' and the 'Issue of equity'. It details a specific transaction where a Non-Executive Director exercised share options. This falls under the category of Director's Dealing (DIRS) as it reports personal share transactions by a company director, and also involves a capital change (SHA). Given the primary focus on the director's transaction disclosure (PDMR notification), DIRS is the most accurate classification.
2018-12-17 English
Consolidation of Trading Lines
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from MaxCyte, Inc. regarding the consolidation of two trading lines of common stock into a single unrestricted line. This involves a change in the company's capital structure and share trading symbols. While it is distributed via RNS (Regulatory News Service), it is a substantive announcement regarding share capital changes rather than a generic regulatory filing or a report publication announcement. Therefore, it fits best under the 'Share Issue/Capital Change' category.
2018-11-21 English
Consolidation of Trading Lines
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from MaxCyte, Inc. regarding the consolidation of two trading lines of common stock into a single unrestricted line. This involves a change in the company's capital structure and share trading symbols. While it mentions regulatory bodies (LSE, RNS), it is specifically an announcement regarding share capital changes and trading mechanics, which falls under the 'Share Issue/Capital Change' category.
2018-11-21 English
Block Admission Six Monthly Return/TVR
Regulatory Filings Classification · 98% confidence The document is a 'Schedule 6 AIM Block Admission Six Monthly Return' filed via the London Stock Exchange's RNS (Regulatory News Service). It details the issuance of shares under a specific incentive plan and provides the total issued share capital. This type of regulatory disclosure regarding share capital changes and block admission returns is best classified under the 'Regulatory Filings' category as it is a standard regulatory reporting requirement for AIM-listed companies that does not fit into specific categories like 'Share Issue' (which usually refers to new capital raises) or 'Director's Dealing'.
2018-11-20 English
Block Admission Six Monthly Return/TVR
Regulatory Filings Classification · 98% confidence The document is a 'Schedule 6 AIM Block Admission Six Monthly Return' filed via the London Stock Exchange's RNS (Regulatory News Service). It details the issuance of shares under a specific incentive plan and provides the total issued share capital. This type of regulatory disclosure regarding share capital changes and block admission returns is best classified under the 'Regulatory Filings' category as it serves as a standard market notification for AIM-listed companies.
2018-11-20 English
Webinar: non-viral cell engineering
Regulatory Filings Classification · 100% confidence The document is an announcement from MaxCyte, Inc. regarding an upcoming webinar for investors and analysts. It is distributed via the London Stock Exchange's RNS (Regulatory News Service). Since it is a general corporate announcement that does not fit into specific categories like financial reports, M&A, or director dealings, it falls under the 'Regulatory Filings' (RNS) category.
2018-11-16 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.